# Huahui Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huahui-health

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.huahuihealth.com
- Total disclosed funding: $78M
- Latest round: Series A (May 1, 2021)
- Investors on record: 9

## About

Established in 2015 and based in Beijing, China, Huahui Health is a biotech company that focuses on the development of drugs in the field of liver disease. The founder team members are from Beijing Institute of Life Sciences. The CEO of the company, Dr. Bin Chen, was the CEO of Beijing Syngentech Co.,LTD, and Dr. Bin Ye, the chief scientific officer, worked in Novartis. In April 2016, Huahui Health launched its first pilot product HH-003.

The company engages in the development of drugs in the field of liver disease. Its main products include the antibody drug HH-003 that cures hepatitis B, the broad-spectrum anti-coronavirus inhalation drug HH-120 and anti-tumor drugs.

## Funding rounds

- Series A, May 1, 2021, $1M — Calor Capital
- Series A, Mar 23, 2021, $77M — MPC, Hankang Capital, GL Ventures
- Series A, Sep 20, 2019 — MPC, Changkejin  Investment, Sherpa Healthcare Partners, Zhongguancun Xingye Investment
- Angel, Mar 16, 2018 — Beijing Capital Science and Technology Development Group Investment Management, Hankang Capital, Wuxi AppTec Group

## Investors

- Beijing Capital Science and Technology Development Group Investment Management (https://capitalatlas.ai/funds/beijing-capital-science-and-technology-development-group-inv) — Angel
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Angel, Series A
- Wuxi AppTec Group — Angel
- MPC — Series A
- Changkejin  Investment — Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A
- Zhongguancun Xingye Investment — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A
- Calor Capital (https://capitalatlas.ai/funds/calor-capital) — Series A